While headlines celebrate a new hair loss drug, the real story is that its active ingredient has been used off label for decades. Veradermics just packaged it in a way that might finally be legal — and patent protected.
Veradermics' experimental hair loss pill works. That much is now settled science: the company's Phase 2/3 trial found that men taking VDPHL01 grew 30 to 33 more hairs per square centimeter of scalp over six months, compared with roughly seven for those on a placebo. Between 79% and 86% said they noticed improvement. The numbers landed Monday and the company's stock rose.
But buried in every headline about a new hair loss breakthrough is a detail most outlets aren't leading with: VDPHL01 is not a new molecule. Its active ingredient is minoxidil — the same blood pressure drug doctors have been prescribing off-label for hair loss since at least the 1990s, often at doses a fraction of the labeled amount, often with unpleasant side effects. What Veradermics did was solve the delivery problem that made the off-label version so hard to tolerate.
Minoxidil was approved as a blood pressure treatment in the 1970s. Dermatologists noticed it grew hair as a side effect; Upjohn eventually developed Rogaine, the topical formulation, which won FDA approval for pattern hair loss in 1988. The oral version never got that approval for hair loss — and for good reason. When people swallow minoxidil tablets, their blood levels of the drug spike and then fall rapidly. At the doses needed to stimulate hair growth, that pattern causes fluid retention, rapid heartbeat, and in some patients pericardial effusion, a dangerous accumulation of fluid around the heart. The off-label users splitting low-dose tablets were essentially tolerating a drug designed for a different purpose, at their own risk.
Veradermics' innovation is an extended-release gel matrix tablet designed to keep minoxidil concentrations in the blood low and steady — high enough to stimulate hair follicles, the company hopes, but below the threshold that triggers cardiac side effects. Whether it achieves that balance at therapeutic doses is the central safety question the FDA will ask when Veradermics files its New Drug Application, expected in 2027.
If the agency signs off, VDPHL01 would become the first and only FDA-approved oral non-hormonal prescription treatment for pattern hair loss in both men and women — a category that has been empty for roughly three decades. The company's patent estate runs through 2043, which means if approval comes, Veradermics — led by dermatologist-turned-CEO Reid Waldman — would own the only legal prescription pathway to oral minoxidil for hair loss for the next two decades.
That is the real business bet. The drug is generic. The market for off-label oral minoxidil already exists: dermatology forums and telehealth platforms have been prescribing it for years, often at costs around $15 a month for the generic tablets. What Veradermics is selling is not the molecule — everyone already has that — but the only version with regulatory approval, a studied safety profile, and a manufacturer with liability protection.
The underground workaround meets the pharmaceutical endgame, is how one analyst covering the company described the dynamic, speaking on background because the company is in a quiet period ahead of its NDA filing.
The competitive picture is not simple. Topical minoxidil, Rogaine's active ingredient, is already widely available over the counter. Finasteride, a hormonal treatment, has been on the market for male pattern hair loss since 1997. The newer entrant spironolactone is used off-label for female pattern hair loss. If VDPHL01 reaches market, its commercial success depends on whether doctors and patients view the extended-release formulation as meaningfully safer than the $15 generic workaround — and whether insurers will cover a branded prescription version at a price that reflects the premium.
The Phase 2/3 trial data released Monday was restricted to men. Women were not included in this readout, despite Veradermics' stated intention to market VDPHL01 as a unisex product. The company has said it is studying the drug in women separately; when those data will read out is not yet public. Until then, the trial's headline efficacy numbers apply only to men.
Cardiac safety data were included in the company's disclosures. Veradermics said there were no serious adverse events and no cardiac adverse events leading to discontinuation. The FDA will make its own assessment during the NDA review. The agency's track record with 505(b)(2) drugs — applications that rely partly on existing data about a known drug rather than entirely new clinical studies — means the approval timeline is shorter than a standard novel molecule pathway, but not guaranteed.
The hair loss market is large and growing. Veradermics cites internal estimates placing it at roughly $30 billion globally by 2028, driven by an aging population and increasing willingness to pay for pharmacological rather than surgical interventions. That figure is doing a lot of work in the company's investor pitch. Whether the actual market develops that way depends on price, coverage, and a simple question that every dermatology investor is quietly calculating: will people take a pill for hair loss as reliably as they slather Rogaine on their scalp and stop after six months — which is what most people do now?
The conference call with investors and analysts took place Monday morning. Veradermics did not disclose a specific price range or commercialization timeline beyond the NDA filing goal. The next data point the FDA will want to see is the full safety dataset from the pivotal trial — and whether the agency's reviewers are convinced that the extended-release mechanism actually solves the cardiac problem that kept oral minoxidil out of the pharmacopeia for hair loss for 30 years.